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Summary: Plasma fibronectin depletion decreases resistance to sepsis. After cardiac surgery, septic complica-
tions occur more frequently when the surgical procedure is managed with a cardio-pulmonary bypass than
when it is not. To determine whether cardio-pulmonary bypass produces a greater decrease in plasma
fibronectin than surgery without cardio-pulmonary bypass, we studied plasma fibronectin concentrations in
two groups of children operated for congenital heart diseases.
Group I: 10 children undergoing surgery with cardio-pulmonary bypass.
Group II: 11 children Undergoing surgery without cardio-pulmonary bypass.
Plasma fibronectin was monitored pre-operatively (t 1) and post-operätively at the 6th hour (t 2), Ist (t 3)
and 7th (t 4) days. In both groups, plasma fibronectin concentration dropped at (t 2) and (t 3) and rose again
at (t 4). There was no significant difference in plasma fibronectin levels between the two groups at any time.
We conclude that the plasma fibronectin decline alone cannot explain why septic complications after surgery
are more freqüeiit with cardio-pulmonary bypass than without.
Verarmung des Plasmas an Fibronectin bei Kindern nach Herzchirurgie mit oder ohne kardiopulmonalen Bypass
Zusammenfassung: Die Verarmung des Plasmas an Fibronectin vermindert die Widerstandskraft gegen Sepsis.
Nach chirurgischen Eingriffen am Herzen treten septische Komplikationen häufiger auf, wenn der Eingriff
mit einem kardiopulmonalen Bypass durchgeführt wird. Wir untersuchten die Konzentration von Fibronectin
im* Plasma bei zwei Gruppen von Kindern, die wegen angeborener Herzfehler operiert wurden, um festzustel-
len, ob der kardiopulmonale Bypass einen bedeutenderen Abfall des Fibronectins im Plasma verursacht als
die Chirurgie ohne Bypass:
Gruppe I: 10 Kinder, die sich einer Operation mit dem kardiopulmonalen Bypass unterzogen;
Gruppe II: 11 Kinder, die sich einer Operation ohne kardiopulmonalen Bypass unterzogen.
Fibronectin im Plasma wurde vor der Operation (t 1) und 6 Stunden (t 2), sowie am 1. (t 3) und 7. Tag (t 4)
danach bestimmt. In beiden Gruppen fiel die Fibronectinkonzentration bei (t 2) und (t 3) und stieg bei (t 4)
wieder an. Es bestand zu keiner Zeit ein signifikanter Unterschied zwischen den Fibronectinkonzentrationen
im Plasma beider Gruppen. Wir schließen daraus, daß der Abfall der Fibronectinwerte im Plasma allein
nicht erklären kann, warum septische Komplikationen nach chirurgischen Eingriffen mit kardiopulmonalem
Bypass häufiger sind als ohne.
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Introduction
Fibronectin is a 440,000 dalton glycoprotein, whose
average plasma concentration is 300 ±100 mg l"1
(1). One of its functions is to stimulate the reticuloen-
dothelial system (RES) thus contributing to the host's
non-immune defences. It also enhances phagocytosis
by peripheral blood monocytes of opsonised particles
(2). Moreover, plasma fibronectin modulates RES
clearance of non bacterial particles and of some bac-
terial species (3, 4). Current opinion indexes the RES
defence potential to the serum immunoreactive fi-
bronectin concentration (5) and plasma fibronectin
deficiency could increase susceptibility to infection
by microbial pathogens (6).
Although cardiac surgery is usually aseptic, some
infectious complications are observed, especially
when the Operation necessitates cardiopulmonary by-
pass. Several hypotheses have been evoked to explain
the higher incidence of infection after cardio-pulmo-
nary bypass: median sternotomy incision (9), impair-
ment of immune system components (10), functional
defect of phagocytic cells, notably polymorpho-
nuclear neutrophils (11).
This work aims to determine whether cardio-pulmo-
nary bypass cardiac surgery induces a significant de-
pletion in the plasma fibronectin concentration äs
compared to cardiac surgery without cardio-pulmo-
nary bypass. Such a depletion could be a factor in
the subsequent higher incidence of infection after
cardio-pulmonary bypass cardiac surgery.
Patients and Methods
This study comprises 21 observations on operated children, who
h ad undergone surgery for congenital heart diseases without
infectious complications. They were divided into 2 groups:
Group I included 10 children aged 9 months to 13 years
(m ± SD; 82 ± 45 months) having .vjndergone surgery with
cardio-pulmonary bypass. Table l summarizes principal clinical
data.
Cardio-pulmonary bypass utilized a membrane oxygenator
(Rhone^Poulenc*). Priming was realized with aliquots of crysta-
loid and blood restored from red blood cells and fresh frozen
plasma. The average volume was 62 ± 15.9 ml kg"1.
Initial heparinization (IH) was 250 units kg"1 prolongated by
constant intravenous injection of 1/4 IH h"1. At the end of
cardio-pulmonary bypass, heparin was neutralized by injection
of 3.25 mg kg"1 of pfotamine sulphate.
Per operative blood compensation ranged from 26.6 to 84.2 ml
kg"1 (x = 60.8 ± 20). Post operative transfusion ranged from
0 to 25.7 ml kg"1 (x = 7.1 ± 7.5) depending on haeniorrhage
and/or loading requirements.
Group II included 11 children aged from 2 to 9 years old (m =
60 ± 28 months) operated without cardio-pulmonary bypass
(table 2 summarizes principal clinical data).
Per operative blood compensation varied from 0 tö 24 ml kg"1
(x = 3.44 ± 7.4). Post operative compensation varied from 0
toSmlkg"1 (x = 2.6 ± 3.3).
Anaesthesia had a mean duration of 297 ± 53 min fpr group I
and 178 ± 51 min for group II.
Blood samples (2 ml) for plasma fibronectin determination were
drawn in glass tubes containing 0.2ml of 38 g l""1 sodium
citrate, either via venous catheter during the post operative
period or via venous puncture at the time of routine pre and
post operative laboratory tests. Four samples were cqllected
for each child: the day before Intervention (t 1), at the 6th post
operative hour (t 2), the Ist post operative day (t 3) and the
7th post operative day (t 4). After centrifugation (1500#, 20
minutes, 4°C) plasma samplesv were immediately frozen arid
stored at —30 °C until the moment of assay.






























































































*) per-operative: Transfusion of blood products (red blood cells, fresh frozen plasma, whole blood) during Intervention and stay
in operating room. ·
post-operative: Transfusion of blood products during the first post-operative 12 hours in Intensive Ca*re Unit.
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Plasma fibronectin was measured by radial immunodiffusion
s described by Mancini (12). Twenty microliters of half diluted
plasma were deposited in t o a well cut in a gel plate containing
anti-human plasma fibronectin antibody (L. C. Partigen,
Hoechst—Behring*). The amount of deposited fibronectin was
determined by measuring the precipitating ring surface. Four
dilutions of a standardized plasma containing a known amount
of plasma fibronectin were used for calibration, the intra-assay
Variation coefficicnls lying between 3% and 4%.
The data were analysed statistically using analysis of covariance
and descriptive sample statistics: Student"1* t-test or Mann-Whit-
ney's non parametric test for intergroup comparison; paired
"t" test or paired Wilcoxorfs non parametric test for intragroup
comparison; results were expressed in mean ± Standard devia-
tion (χ ± SD). Correlation between 2 variables was researched




Initial plasma fibronectin mean levels (383 ± 59
mg l"1) declined to 314 + 52 mg l""1 at the 6th hour
and further to 270 + 26 mg l"1 the day after the
Operation, then rose to 330 + 36 mg l"1 on the
7th day. Statistical analysis demonstrated that^Ml
subgroups (l, 2, 3, 4) were mutually different (fig. 1).
Group II
Pre operative plasma fibronectin mean level also de-
clined from 344 ± 71 mg l"1 to 309 ± 75 mgl"1 at
the 6th post operative hour and to 234 + 76 mg l"1
on the Ist post operative day, then rose to 362 +
77 mg on the 7th post operative day. Results of the
Statistical analyses are given on figure 1.
There was no significant difference in the temporal
evolution of plasma fibronectm between group I and
group II.
Tab. 2. Group II: princip l clinical data.























































































*) S. table l
Fig. 1. Concentrations of fibronectin in plasma.
The data represent mean values with respective Standard
deviations.
*p: significant differences from the pre- and post-oper-
ative values
**p: significant difference from post-operative 6th hour
and lsl day
***p: sigoificant differences from post-operative lsl day
and 7th day.
Discussion
Pre-operative plasma fibronectin levels of our
patients were similar to those already reported (l,
13). Since the pre-operative values of group I and
group II did not differ in variance and mean, we were
able to regroup the 21 patients into one group to
determine if a correlation existed between the initial
level of plasma fibronectin and age, s previously
reported (13). In our group of 21 children there was
no correlation (r = 0.08).
This disagreement with the results reported by
Eriksen et al. (13) may be due to the fact that in their
series, 23 children under 10 years of age were mixed
with a population of 374 patients aged from a few
months to 85 years. In fact, for the children under
15 years old, plasma fibronectin values furnished by
Eriksen were approximately stable and identical to
those which we found. Thus, our results should not
be biased by age.
Among the children operated with cardio-pulmonary
bypass we recorded a significant decline in plasma
fibronectin concentration at the 6th post operative
hour, continuing the following day (see fig. 1). By
the 7th post operative day the plasma fibronectin
concentration had risen to a level somewhat lower
than the initial pre-operative level. These results agree
with those reported after aortocoronary bypass
among adults (14). Of course, the decrease in plasma
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 7
444 Labrousse et al.: Fibronectin depletion after cardiac surgery
fibronectin concentration after cardio-pulmonary by-
pass could be attributed to an increased utilization
or to dilution (14).
Increased utilization would occur if fibronectin were
involved in the opsonization of microparticles put
into circulation during cardio-pulmonary bypass
(fragmented red corpuscles, diverse tissue frägments
arising from recuperative aspirations, etc... or by
fixation in the extracorporeal circuit, äs previously re-
ported after haemoperfusion in drug intoxicated
patients (15). However, haemodialysis in chronic ura-
emic patients did not lower plasma fibronectin levels
(16).
In children, the plasma fibronectin decline might be
due to dilution owing to the relative importance of
the cardio-pulmonary bypass circuit priming volume
compared with the blood volume (see tab. 1). How-
ever, no relation between the percentage Variation of
plasma fibronectin and the volume of the cardio-
pulmonary bypass circuit (r = —0.44) was found.
Transfusion with blood derivatives could be a pertur-
bation factor, äs patients operated with cardio-pul-
monary bypass received an important Volumetrie
compensation averaging two thirds to three fourths of
their blood volume. This compensation was obtained
with fresh frozen plasma and globular concentrates.
We determined the plasma fibronectin concentration
in 27 fresh frozen blood bank plasmas, immediately
after thawing. The average concentration was 257 +
79 mg l"1. Thus, äs the transfused plasma contained
less fibronectin than that lost by the patients, an
effect of transfusion on the plasma fibronectin con-
centration would probably be dilutive. However there
was no relation between the fall in plasma fibronectin
and the volume of blood transfusions (r = 0.33).
In addition, group II received an average volume
compensation (3.44 ± 74 ml k£~~1) much less than
that received by group I (60.8 ± 20.4 ml kg-1). How-
ever, among group children, the depletion of
plasma fibronectin is comparable to that observed
among the group I children, and the post-operative
levels are not significantly different between the chil-
dren operated with or without cardio-pulmonary by-
pass.
Thus, it does not appear that the utilisation of cardio-
pulmonary bypass (extra corporeäl circuit with allen
material, volume repletion dilution, heparinization,
etc...) is in itself responsible for the post operative
depletion of plasma fibronectin. It is probable that
the surgical Intervention in itself is capable of provo-
king this perturbation.
The absence of a significant difference between
groups I and II may be due to the small sample size.
However, if a large sample size had been employed
it could at most demonstrate a minimal difference
between group I and group II, äs a significant diffe-
rence would have been demonstrated even with a
small population. Finally, even a minimal difference
in plasma fibronectin would still be insufficient to
explain the increased incidence of infection after car-
dio-pulmonary bypass surgery äs compared to non
cardio-pulmonary bypass surgery.
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